Related Experiment Video
Updated: Jun 26, 2025
08:23
Implementation of Minimally Invasive Brain Tumor Resection in Rodents for High Viability Tissue Collection
Published on: May 9, 2022
4.4K
Optimizing perampanel monotherapy for surgically resected brain tumors.
Utaro Hino1, Ryota Tamura1, Kenzo Kosugi1
1Department of Neurosurgery, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan.
Molecular and Clinical Oncology
|May 17, 2024
Summary
Perampanel (PER) monotherapy shows promise for controlling seizures in brain tumor patients, comparable in efficacy and safety to levetiracetam (LEV). Further research is needed to confirm these findings in larger clinical studies.
Area of Science:
- Neuroscience
- Oncology
- Pharmacology
Background:
- Perampanel (PER) is an antiseizure medication (ASM) with a unique mechanism of action, approved for combination therapy in 2016 and monotherapy in 2020.
- PER has demonstrated in vitro antitumor effects, but its efficacy as monotherapy for seizure control in brain tumor patients is not well-established.
Purpose of the Study:
- To evaluate the efficacy and safety of perampanel (PER) monotherapy for seizure control in patients with brain tumors.
- To compare PER monotherapy with levetiracetam (LEV) in this patient population.
Main Methods:
- Retrospective analysis of 25 patients with brain tumors treated with PER monotherapy.
- Comparison with 45 patients treated with levetiracetam (LEV).
- Analysis of seizure frequency and adverse events.
Main Results:
- Seizure occurrence was 8.0% in the PER group and 11.1% in the LEV group, with no significant difference.
- Adverse effect incidence was 12.0% for PER and 2.2% for LEV, also not significantly different.
- Observed adverse effects included mild liver dysfunction and drug rash in the PER group, and drug rash in the LEV group.
Conclusions:
- Perampanel (PER) monotherapy appears to be a safe and potentially effective option for seizure treatment or prophylaxis in patients with brain tumors.
- Larger-scale clinical studies are warranted to further validate these findings.
